IDYA Stock Forecast & Price Target

IDEAYA Biosciences is supported by a differentiated oncology platform with multiple shots on goal, led by IDE849 in DLL3 where the target is highly validated in aggressive neuroendocrine tumors and the addressable U.S. opportunity exceeds $4.5Bn in treatment-naive ES-SCLC and epNEC. The company’s outlook is strengthened by encouraging clinical readthrough for darovasertib, positive FDA interactions for IDE849, and a planned randomized Phase 3 monotherapy study in ES-SCLC by YE26, all of which improve the visibility of future development milestones. Financially, the recent $345M offering lifted pro forma cash to about $1.3B, while the prospect of NDA completion in 2H:26 and advancing combination programs with IDE397 and IDE892 supports a long runway and multiple catalysts.

IDEAYA Biosciences is viewed negatively because its lead programs remain highly exposed to clinical readouts in crowded and competitive markets, where IDE849 must deliver best-in-class efficacy and safety versus multiple ADC competitors while still meeting investor expectations for >60%-65% ORR, >6mo mPFS, and low discontinuation rates. The investment case is also weakened by explicit clinical, regulatory, and commercial failure risk across darovasertib, IDE397, and IDE849, as any shortfall in efficacy or safety could halt development or limit approval prospects. Financially, the company is likely to need additional equity financing to complete development, creating dilution risk for existing shareholders and reinforcing the view that fundamental downside remains elevated.